Applied Therapeutics (APLT) officer cashes out shares in $0.088-per-share merger

Rhea-AI Filing Summary

Applied Therapeutics officer Constantine Chinoporos reported equity changes tied to a merger and prior equity awards. On December 19, 2025, he received 437,500 compensatory RSUs at $0 under the 2019 Equity Incentive Plan, each RSU representing one share that would vest upon a change in control or by June 19, 2026, if he remained in service.

The filing also corrects earlier administrative errors that had overstated his total holdings. Following completion of a tender offer and merger effective January 28, 2026, each Applied Therapeutics common share was cancelled and converted into $0.088 in cash plus one non‑tradeable contingent value right. On February 3, 2026, he reported disposition of 1,000,000 shares and a final 57,111‑share adjustment, leaving zero shares directly owned after the merger consideration was received.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chinoporos Constantine

(Last) (First) (Middle)

C/O APPLIED THERAPEUTICS, INC.

545 FIFTH AVENUE, SUITE 1400

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Applied Therapeutics, Inc. [ APLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/19/2025		A(1)		437,500	A	$0	1,057,111(2)	D
Common Stock	02/03/2026		D(3)(4)		1,000,000	D	(3)(4)	57,111	D
Common Stock	02/03/2026		U(3)(5)		57,111	D	(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.

2. The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.

3. Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

4. Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.

5. Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

Remarks:

Chief Operating Officer and Chief Business Officer

	/s/ Leslie D. Funtleyder, as attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Constantine Chinoporos report at Applied Therapeutics (APLT)?

He reported a grant of 437,500 restricted stock units and later dispositions of 1,000,000 Applied Therapeutics common shares plus a 57,111-share adjustment. These changes reflect merger-related consideration and a final correction of his directly held share count to zero.

When were RSUs granted to Constantine Chinoporos at Applied Therapeutics (APLT)?

He received 437,500 compensatory RSUs on December 19, 2025 at a price of $0 per unit. Each RSU represents one share of Applied Therapeutics common stock, vesting upon a change in control or by June 19, 2026, subject to continued service.

How did the Applied Therapeutics (APLT) merger affect common shareholders?

At the merger’s effective time on January 28, 2026, each Applied Therapeutics common share was cancelled and converted into $0.088 in cash plus one non-tradeable contingent value right. This combined package is defined as the merger consideration in the merger agreement.

What share dispositions did Constantine Chinoporos report after the Applied Therapeutics (APLT) merger?

On February 3, 2026, he reported disposition of 1,000,000 common shares at a stated price of $0 per share under merger terms, plus a 57,111-share adjustment. After these entries, his reported directly owned common share balance was reduced to zero.

Why were Constantine Chinoporos’ Applied Therapeutics (APLT) holdings adjusted in this Form 4?

The filing explains that his total holdings were revised to correct an administrative error in prior Form 4 filings. Those earlier reports had overstated his beneficial holdings, and this Form 4 aligns the reported balance with the corrected share count.

How were Constantine Chinoporos’ RSUs treated in the Applied Therapeutics (APLT) merger?

Under the merger agreement, each outstanding RSU, vested or unvested, was deemed to have vested at the effective time. Each was cancelled and automatically converted into the right to receive the same merger consideration as common shares.